PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19758923-6	2005	CONCLUSION: After PCI in UA, cyclooxygenase-2 inhibitor rofecoxib added to atorvastatin reduced CRP and IL-6 levels more profoundly than atorvastatin alone at 3- and 6-month after intervention.	rofecoxib	56-65	interleukin 6	Homo sapiens	104-108	
17950038-9	2008	Rofecoxib significantly decreased regional IL-6 and TNF-alpha level after surgery.	rofecoxib	0-9	interleukin 6	Homo sapiens	43-47	
17950038-10	2008	Moreover, the incidence of febris and degree of local edema were lower in the rofecoxib group (P < .05), and peripheral IL-6 level significantly correlated with pain score at 48 hours.	rofecoxib	78-87	interleukin 6	Homo sapiens	123-127	
17070997-5	2007	Both rofecoxib and ibuprofen treatment increased the gene expression of the pro-inflammatory mediators, IL6 and CCL2 (chemokine C-C motif ligand 2), following tissue injury compared to the placebo treatment.	rofecoxib	5-14	interleukin 6	Homo sapiens	104-107	
17673806-4	2007	[Melanoma Res 2006;16:263-265] of remission of an advanced melanoma during treatment with the cyclooxygenase, (COX) inhibitor rofecoxib can be explained by rofcoxib-mediated lowering of tumor-produced Il-6.	rofecoxib	126-135	interleukin 6	Homo sapiens	201-205	
17673806-5	2007	Several examples of rofecoxib"s ability to lower Il-6 in humans have been published recently in other settings, and many reports indicate that other commonly used COX inhibitors like aspirin, diclofenac, etodolac, indomethacin, naproxen, and many others, also lower Il-6 in humans.	rofecoxib	20-29	interleukin 6	Homo sapiens	49-53	
17673806-5	2007	Several examples of rofecoxib"s ability to lower Il-6 in humans have been published recently in other settings, and many reports indicate that other commonly used COX inhibitors like aspirin, diclofenac, etodolac, indomethacin, naproxen, and many others, also lower Il-6 in humans.	rofecoxib	20-29	interleukin 6	Homo sapiens	266-270	
16330117-6	2006	RESULTS: Malondialdehyde, C-reactive protein and interleukin-6 levels were reduced in the rofecoxib group (p=0.04, p=0.003 and p=0.02 respectively) while they remained unchanged in the placebo group after 1 week of treatment.	rofecoxib	90-99	interleukin 6	Homo sapiens	49-62	
15302800-6	2004	Rofecoxib compared with placebo also lowered IL-6 at 6 months (P=0.0002).	rofecoxib	0-9	interleukin 6	Homo sapiens	45-49	
15302800-7	2004	There was a significant off-drug effect on CRP and IL-6 levels in the rofecoxib group 3 months after treatment (P=0.005 and P=0.009, respectively).	rofecoxib	70-79	interleukin 6	Homo sapiens	51-55	
15136366-0	2004	Rofecoxib, a COX-2 inhibitor, lowers C-reactive protein and interleukin-6 levels in patients with acute coronary syndromes.	rofecoxib	0-9	interleukin 6	Homo sapiens	60-73	
15136366-2	2004	AIM: To evaluate whether patients with ACS treated with rofecoxib, a COX-2 inhibitor, will have reduced CRP, IL-6, and soluble tumor necrotic factor receptor-1 (sTNF-R1) levels and improved endothelial function.	rofecoxib	56-65	interleukin 6	Homo sapiens	109-113	
15136366-6	2004	IL-6 levels were significantly lower at 1 month (p < 0.02) in the rofecoxib group, but not at 3 months.	rofecoxib	69-78	interleukin 6	Homo sapiens	0-4	
15136366-8	2004	CONCLUSION: Patients recovering from ACS had lower levels of CRP and IL-6 at 1 month and lower CRP levels at 3 months when treated with rofecoxib plus aspirin.	rofecoxib	136-145	interleukin 6	Homo sapiens	69-73